Navigation Links
Chimerix Announces Late-Breaker Presentation at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting
Date:9/16/2011

irus (HSV), and JC virus (JCV), for which there are no FDA-approved treatments or where patients have failed available treatments. There is no evidence of otherwise unexplained nephrotoxicity or myelosuppression in these immunocompromised patients. These data support positive interim results seen in CMX001's ongoing Phase 2 placebo-controlled clinical trial evaluating the safety, tolerability and ability of CMX001 to prevent or control CMV infection in R+ hematopoietic cell transplant (HCT) recipients.  

About CMX001

CMX001 is an oral Lipid-Antiviral-Conjugate (LAC) that delivers high intracellular levels of the active antiviral agent cidofovir-diphosphate.  Its broad spectrum activity against double-stranded DNA (dsDNA) viruses without the myelotoxicity and nephrotoxicity of current agents has the potential to improve outcomes for immunosuppressed patients.  In development for the treatment or prevention of life-threatening dsDNA viral diseases, more than 600 patients have been dosed with CMX001 in placebo-controlled clinical trials and open-label treatment protocols.  More than 300 of these individuals have received CMX001 under Emergency Investigational New Drug Applications (EINDs) or as part of the CMX001-350 Open-Label Study to help treat life-threatening dsDNA viral diseases for which there were no other therapeutic options.  CMX001 is also being developed as a biodefense countermeasure in the event of a smallpox release.  The growing body of evidence of CMX001's antiviral activity against all five families of dsDNA viruses that cause disease in humans, including smallpox, has strengthened the compound's potential as a dual-use product prescribed as a traditional pharmaceutical and stockpiled as a biodefense countermeasure.  

Clinical studies of CMX001 include an ongoing Phase 2 study for the prevention cytomegalovirus (CMV) in adult hematopoietic cell transplant patients (CMX001-201); a Phase 2 s
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
2. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
3. Chimerix to Present at Two Upcoming Investor Conferences
4. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
5. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
6. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
7. Chimerix to Present at 9th Annual BIO Investor Forum
8. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
9. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
10. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
11. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... Noser Health and Netcetera ... deliver new platform   ... data transaction platform, announced today strategic partnerships with ... and bring to market its global health data transaction ... "Our business model is built on trust, neutrality, impact ...
(Date:8/28/2015)... , Aug. 28, 2015  CytomX Therapeutics, Inc., ... of cancer, today announced the filing of a registration ... Exchange Commission (SEC) relating to a proposed initial public ... to be offered and the price range for the ... list its common stock under the symbol "CTMX" on ...
(Date:8/28/2015)... 28, 2015 Research and ... the "Investigation Report on China,s Tobramycin Market, 2010-2019" ... a traditional antibiotic whose eye drop and ointment are ... potential infection or inflammation caused by eye infection. Currently, ... are able to produce tobramycin, among which the Top ...
Breaking Medicine Technology:healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 2healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 3healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 4CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Tobramycin Market, 2015-2019 2
... 3 Cornerstone Therapeutics Inc. (Nasdaq: ... specialty pharmaceutical company focused on acquiring, developing and commercializing ... today announced that the Company has licensed to Targacept, ... patents and library of preclinical compounds that target the ...
... , SHANGHAI , ... Shanghai based,life science research service company, and Bio ... research service company, announced today the completion of,a ... The company is using the,funding to scale research & ...
Cached Medicine Technology:Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept 2Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept 3Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept 4Sangon & Bio Basic Inc. Closes $10 Million Round of Investment by Qiming Ventures 2Sangon & Bio Basic Inc. Closes $10 Million Round of Investment by Qiming Ventures 3
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... their peers may be at a greater risk for injury, potentially because they ... a University of Pittsburgh Graduate School of Public Health analysis discovered. , ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... On Saturday, ... A Mission” at the Adams County Fairgrounds in Mendon, IL. The purpose behind this ... districts of Mendon and neighboring town, Quincy. Best Drug Rehabilitation’s sponsorship of “Music with ...
(Date:8/31/2015)... ... August 31, 2015 , ... “My mother and husband use oxygen therapy ... Ky. “I thought there could be a comfortable way to prevent the irritation, so ... Ear Protector offers a more secure way to anchor the cannula tubing used in ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... medical professional association for physicians and allied health professionals dedicated to using ... Foundation, announced today the establishment of the Lifestyle Medicine Lifetime Achievement and ...
(Date:8/31/2015)... ... August 31, 2015 , ... Chicago-based company The Mood Factory, ... raise money and awareness for breast and ovarian health. During September and ... Mood-lite sold to Bright Pink® to encourage households, dorms, and offices around the ...
Breaking Medicine News(10 mins):Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 2Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 3Health News:2015 "Music With A Mission" Sponsor Best Drug Rehabilitation Releases Artist Compilation Video 2Health News:2015 "Music With A Mission" Sponsor Best Drug Rehabilitation Releases Artist Compilation Video 3Health News:InventHelp® Inventor Designs Nasal Cannula Ear Protector (AVZ-1217) 2Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 2Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 3Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 2Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 3
... by drug researchers has revealed that enabling controlled doses of ... //would serve a dual purpose – of bringing down the ... for a year will come down drastically. , ,National ... perhaps the first ever cost-benefit study of a prison methadone ...
... to information by the Canadian government a confirmed case of ... found. // ,The case was of a 6-year-old ... through a national surveillance program for mad-cow disease. ,In ... of Canadian beef. Tissues in which BSE is known to ...
... According to a Johns Hopkins University behavioral neuroscientist evidence is ... neurotransmitter when acting in the brain. // The study was ... the same direction is an article by Gregory Ball, professor ... university's Krieger School of Arts and Sciences, to be published ...
... rescue group has raised concerns over swans and other wild birds ... //. Despite pleas from wildlife rescue groups, Canada geese, peregrine falcons ... attempts of Salisbury Wildlife Rescue workers to save a swan (found ... up in vain. The bird had to be eventually destroyed by ...
... lack of sleep in children, could lead to obesity. ... faculty of medicine studied 422 grade school students aged ... waist size of each participant. ,They also ... through phone interviews with their parents, reported health portal ...
... the country focuses on headline-grabbing diseases, hemophilia, a little known ... with over 50,000 people affected. // ,World ... global effort to secure appropriate care and treatment for a ... by a defect in the genes. ,"The disease ...
Cached Medicine News:Health News:Cost-Benefit Economics of Methadone for prisoners 2
BETADINE® Surgical Scrub is a microbicidal, sudsing cleanser that promptly kills most bacteria, fungi, viruses, protozoa and yeasts. It is indicated for hand hygiene, surgical hand-scrubbing, an...
... Topical, Bactericide, Microbicide for professional ... technology in skin disinfectants combining quaternary ... a synergistic blend of emollients and ... and gram-positive organisms tested in 30 ...
... bonds with the skin ... germ-killing field. In addition ... antimicrobial effect, HIBICLENS' non-drying, ... promotes compliance with the ...
... solution, allows the user to prep one ... in less than 2-minutes. It also utilizes ... surgical scrubbing and healthcare personnel handwashing. ACTIPREP ... provide a tacky surface for drapes to ...
Medicine Products: